Matches in SemOpenAlex for { <https://semopenalex.org/work/W48603991> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W48603991 abstract "Background: New oral anticoagulants (NOAC) have been approved in a number of countries for long-term anticoagulation in atrial fibrillation (AF) and venous thromboembolism (VTE). Currently, many patients are switched from Vitamin-K antagonists (VKA) to NOAC. We evaluated the transition process (time gap between last intake of VKA, last INR sampling and first intake of NOAC) in unselected patients from daily care. Patients and methods: A network of 115 physicians from private practice and hospitals enrol patients in the NOAC registry. Inclusion criteria are: 1) indication for NOAC anticoagulation >3 month; 2) age > 18 years; 3) written informed consent; 4) availability for follow-up. No Exclusion criteria apply. Patients are prospectively followed by phone visits at day 30 day and quarterly thereafter to collect efficacy and safety data. Results: Until June 6 th 2012, 683 patients were registered. Of the 266 patients switched from VKA, data on the transition process were available in 213 patients (70.0% AF, 30.0% VTE). Of these, only 104 patients (48.8%) had a recorded INR measurement at the end or within 7 days before the end of VKA treatment (mean INR 2.4 for all, 2.6 in AF and 2.1 in VTE patients; table 1). In patients with INR tests, time between last INR and start of NOAC was around 3 days (5 days in AF and 2 days in VTE patients). For all patients, time between last VKA and start NOAC was around 7 days (8 days in AF; 4 days in VTE patients). Conclusion: In unselected patients in daily care, only 50% of patients have a documented INR test before NOAC is started. Despite documented INR values in the lower therapeutic range, physicians are reluctant to start NOAC therapy immediately and allow for another 2 to 5 days before NOAC is started. However, no major vascular events or major bleedings were observed in VKA transition patients at day 30, indicating that this procedure is safe." @default.
- W48603991 created "2016-06-24" @default.
- W48603991 creator A5004003194 @default.
- W48603991 creator A5014120212 @default.
- W48603991 creator A5036538563 @default.
- W48603991 creator A5037644466 @default.
- W48603991 creator A5045063067 @default.
- W48603991 creator A5061586983 @default.
- W48603991 creator A5072985354 @default.
- W48603991 creator A5075247673 @default.
- W48603991 date "2012-11-20" @default.
- W48603991 modified "2023-10-06" @default.
- W48603991 title "Abstract 18238: Transition from Vitamin-K-antagonists to New Oral Anticoagulants in Daily Care - First Results of the Prospective NOAC Registry (NCT 01588119)" @default.
- W48603991 hasPublicationYear "2012" @default.
- W48603991 type Work @default.
- W48603991 sameAs 48603991 @default.
- W48603991 citedByCount "0" @default.
- W48603991 crossrefType "journal-article" @default.
- W48603991 hasAuthorship W48603991A5004003194 @default.
- W48603991 hasAuthorship W48603991A5014120212 @default.
- W48603991 hasAuthorship W48603991A5036538563 @default.
- W48603991 hasAuthorship W48603991A5037644466 @default.
- W48603991 hasAuthorship W48603991A5045063067 @default.
- W48603991 hasAuthorship W48603991A5061586983 @default.
- W48603991 hasAuthorship W48603991A5072985354 @default.
- W48603991 hasAuthorship W48603991A5075247673 @default.
- W48603991 hasConcept C120665830 @default.
- W48603991 hasConcept C121332964 @default.
- W48603991 hasConcept C126322002 @default.
- W48603991 hasConcept C187212893 @default.
- W48603991 hasConcept C188816634 @default.
- W48603991 hasConcept C2779161974 @default.
- W48603991 hasConcept C2780868729 @default.
- W48603991 hasConcept C2991741193 @default.
- W48603991 hasConcept C2993590494 @default.
- W48603991 hasConcept C61511704 @default.
- W48603991 hasConcept C71924100 @default.
- W48603991 hasConceptScore W48603991C120665830 @default.
- W48603991 hasConceptScore W48603991C121332964 @default.
- W48603991 hasConceptScore W48603991C126322002 @default.
- W48603991 hasConceptScore W48603991C187212893 @default.
- W48603991 hasConceptScore W48603991C188816634 @default.
- W48603991 hasConceptScore W48603991C2779161974 @default.
- W48603991 hasConceptScore W48603991C2780868729 @default.
- W48603991 hasConceptScore W48603991C2991741193 @default.
- W48603991 hasConceptScore W48603991C2993590494 @default.
- W48603991 hasConceptScore W48603991C61511704 @default.
- W48603991 hasConceptScore W48603991C71924100 @default.
- W48603991 hasLocation W486039911 @default.
- W48603991 hasOpenAccess W48603991 @default.
- W48603991 hasPrimaryLocation W486039911 @default.
- W48603991 hasRelatedWork W1934003446 @default.
- W48603991 hasRelatedWork W2112731527 @default.
- W48603991 hasRelatedWork W2283332857 @default.
- W48603991 hasRelatedWork W2517024478 @default.
- W48603991 hasRelatedWork W2526905960 @default.
- W48603991 hasRelatedWork W2552194471 @default.
- W48603991 hasRelatedWork W2582601412 @default.
- W48603991 hasRelatedWork W2606898993 @default.
- W48603991 hasRelatedWork W2612684627 @default.
- W48603991 hasRelatedWork W2765450172 @default.
- W48603991 hasRelatedWork W2783117367 @default.
- W48603991 hasRelatedWork W2807635628 @default.
- W48603991 hasRelatedWork W2883889056 @default.
- W48603991 hasRelatedWork W2924424410 @default.
- W48603991 hasRelatedWork W2979369259 @default.
- W48603991 hasRelatedWork W2979758517 @default.
- W48603991 hasRelatedWork W2981847567 @default.
- W48603991 hasRelatedWork W2989627922 @default.
- W48603991 hasRelatedWork W3143310844 @default.
- W48603991 hasRelatedWork W5418977 @default.
- W48603991 hasVolume "126" @default.
- W48603991 isParatext "false" @default.
- W48603991 isRetracted "false" @default.
- W48603991 magId "48603991" @default.
- W48603991 workType "article" @default.